6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Takeda	NNP	takeda	takeda	takeda	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
TAKEDA	NNP	takeda	takeda	takeda	N	O
-	:	-	-	-	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
3327	CD	3327	3327	3327	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Studies	NNS	studies	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Approximately	RB	approximately	approximately	approxim	N	O
8500	CD	8500	8500	8500	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
in	IN	in	in	in	N	O
14	CD	14	14	14	N	O
randomized	NNS	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
approximately	RB	approximately	approximately	approxim	N	O
2900	CD	2900	2900	2900	N	O
subjects	NNS	subjects	subject	subject	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
approximately	RB	approximately	approximately	approxim	N	O
2200	CD	2200	2200	2200	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
comparator	NN	comparator	comparator	compar	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
was	VBD	was	wa	wa	N	O
40	CD	40	40	40	N	O
weeks	NNS	weeks	week	week	N	O
with	IN	with	with	with	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
2400	CD	2400	2400	2400	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBD	treated	treated	treat	N	O
for	IN	for	for	for	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
63%	CD	63%	63%	63%	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
,	,	,	,	,	N	O
51%	CD	51%	51%	51%	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
dyslipidemia	NN	dyslipidemia	dyslipidemia	dyslipidemia	Y	O
,	,	,	,	,	N	O
25%	CD	25%	25%	25%	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	O
infarction	NN	infarction	infarction	infarct	Y	O
,	,	,	,	,	N	O
8%	CD	8%	8%	8%	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
unstable	JJ	unstable	unstable	unstabl	N	O
angina	NN	angina	angina	angina	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
was	VBD	was	wa	wa	N	O
seven	CD	seven	seven	seven	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	NN	mean	mean	mean	N	O
body	NN	body	body	bodi	N	O
mass	NN	mass	mass	mass	Y	O
index	NN	index	index	index	N	O
(	(	(	(	(	N	O
BMI	NNP	bmi	bmi	bmi	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
31	CD	31	31	31	N	O
kg	JJ	kg	kg	kg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
51%	CD	51%	51%	51%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
BMI	NNP	bmi	bmi	bmi	N	O
30	CD	30	30	30	N	O
kg	NNP	kg	kg	kg	N	O
m	FW	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
was	VBD	was	wa	wa	N	O
57	CD	57	57	57	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
12	CD	12	12	12	N	O
and	CC	and	and	and	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
duration	NN	duration	duration	durat	N	O
were	VBD	were	were	were	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
12.5	CD	12.5	12.5	12.5	N	O
mg	JJ	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	JJ	mg	mg	mg	N	O
daily	JJ	daily	daily	daili	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
add	SYM	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
combination	NN	combination	combination	combin	N	O
therapy	NN	therapy	therapy	therapi	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
duration	NN	duration	duration	durat	N	O
were	VBD	were	were	were	N	O
also	RB	also	also	also	N	O
conducted	VBN	conducted	conducted	conduct	N	O
:	:	:	:	:	N	O
with	IN	with	with	with	N	O
metformin	NNS	metformin	metformin	metformin	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
thiazolidinedione	NN	thiazolidinedione	thiazolidinedione	thiazolidinedion	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
16	CD	16	16	16	N	O
weeks	NNS	weeks	week	week	N	O
up	RB	up	up	up	N	O
through	IN	through	through	through	N	O
two	CD	two	two	two	N	O
years	NNS	years	year	year	N	O
in	IN	in	in	in	N	O
duration	NN	duration	duration	durat	N	O
were	VBD	were	were	were	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
metformin	NN	metformin	metformin	metformin	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
pioglitazone	NN	pioglitazone	pioglitazone	pioglitazon	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
pioglitazone	NN	pioglitazone	pioglitazone	pioglitazon	N	O
added	VBD	added	added	ad	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
background	NN	background	background	background	N	O
of	IN	of	of	of	N	O
metformin	NN	metformin	metformin	metformin	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
duration	NN	duration	duration	durat	N	O
were	VBD	were	were	were	N	O
conducted	VBN	conducted	conducted	conduct	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
pioglitazone	NN	pioglitazone	pioglitazone	pioglitazon	N	O
and	CC	and	and	and	N	O
metformin	NN	metformin	metformin	metformin	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
metformin	NN	metformin	metformin	metformin	N	O
and	CC	and	and	and	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
glipizide	VB	glipizide	glipizide	glipizid	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
14	CD	14	14	14	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
66%	CD	66%	66%	66%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
62%	CD	62%	62%	62%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
70%	CD	70%	70%	70%	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
comparator	NN	comparator	comparator	compar	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
or	CC	or	or	or	N	O
6.2%	CD	6.2%	6.2%	6.2%	N	O
with	IN	with	with	with	N	O
active	JJ	active	active	activ	N	O
comparator	NN	comparator	comparator	compar	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
are	VBP	are	are	are	N	O
summarized	VBN	summarized	summarized	summar	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
Patients	NNS	patients	patient	patient	N	O
Treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
More	RBR	more	more	more	N	O
Frequently	RB	frequently	frequently	frequent	N	O
Than	NNP	than	than	than	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
Given	NNP	given	given	given	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Pooled	NNP	pooled	pooled	pool	N	O
Studies	NNS	studies	study	studi	N	O

Number	NNP	number	number	number	N	O
of	IN	of	of	of	N	O
Patients	NNP	patients	patient	patient	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

NESINA25	NNP	nesina25	nesina25	nesina25	N	O
mg	NN	mg	mg	mg	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Active	NNP	active	active	activ	N	O
Comparator	NNP	comparator	comparator	compar	N	O

N	NNP	n	n	n	N	O
5902	CD	5902	5902	5902	N	O
N	NNP	n	n	n	N	O
2926	CD	2926	2926	2926	N	O
N	NNP	n	n	n	N	O
2257	CD	2257	2257	2257	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
257	CD	257	257	257	N	O
(	(	(	(	(	N	O
4.4	CD	4.4	4.4	4.4	N	O
)	)	)	)	)	N	O
89	CD	89	89	89	N	O
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	O
)	)	)	)	)	N	O
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
247	CD	247	247	247	N	O
(	(	(	(	(	N	O
4.2	CD	4.2	4.2	4.2	N	O
)	)	)	)	)	N	O
72	CD	72	72	72	N	O
(	(	(	(	(	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
121	CD	121	121	121	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
247	CD	247	247	247	N	O
(	(	(	(	(	N	O
4.2	CD	4.2	4.2	4.2	N	O
)	)	)	)	)	N	O
61	CD	61	61	61	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
5.0	CD	5.0	5.0	5.0	N	O
)	)	)	)	)	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

In	IN	in	in	in	N	O

the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
program	NN	program	program	program	N	O
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11	CD	11	11	11	N	O
of	IN	of	of	of	N	O
5902	CD	5902	5902	5902	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	VBD	mg	mg	mg	N	O
daily	RB	daily	daily	daili	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
five	CD	five	five	five	N	O
of	IN	of	of	of	N	O
5183	CD	5183	5183	5183	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
with	IN	with	with	with	N	O
all	DT	all	all	all	N	O
comparators	NNS	comparators	comparators	compar	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
sickness	NN	sickness	sickness	sick	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

Hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
documented	VBN	documented	documented	document	N	O
based	VBN	based	based	base	N	O
upon	IN	upon	upon	upon	N	O
a	DT	a	a	a	N	O
blood	NN	blood	blood	blood	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
value	NN	value	value	valu	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
clinical	JJ	clinical	clinical	clinic	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
study	NN	study	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
glyburide	VB	glyburide	glyburide	glyburid	N	O
or	CC	or	or	or	N	O
insulin	VB	insulin	insulin	insulin	Y	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
study	NN	study	study	studi	N	O
comparing	VBG	comparing	comparing	compar	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
in	IN	in	in	in	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
5.4%	CD	5.4%	5.4%	5.4%	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
26%	CD	26%	26%	26%	N	O
with	IN	with	with	with	N	O
glipizide	NN	glipizide	glipizide	glipizid	N	O
(	(	(	(	(	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Incidence	NN	incidence	incidence	incid	N	O
and	CC	and	and	and	N	O
Rate	NNP	rate	rate	rate	N	O
of	IN	of	of	of	N	O
HypoglycemiaAdverse	NNP	hypoglycemiaadverse	hypoglycemiaadverse	hypoglycemiaadvers	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
all	DT	all	all	all	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-Severity
and	CC	and	and	and	N	O
asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
;	:	;	;	;	N	O
a	DT	a	a	a	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
glucose	JJ	glucose	glucose	glucos	Y	O
measurement	NN	measurement	measurement	measur	N	O
was	VBD	was	wa	wa	N	O
not	RB	not	not	not	N	O
required	VBN	required	required	requir	N	O
;	:	;	;	;	N	O
intent	JJ	intent	intent	intent	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
-	:	-	-	-	N	O
treat	NN	treat	treat	treat	N	O
population	NN	population	population	popul	N	O
.	.	.	.	.	N	O

in	IN	in	in	in	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
Active	NNP	active	active	activ	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Studies	NNS	studies	study	studi	N	O
when	WRB	when	when	when	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
Was	NNP	was	wa	wa	N	O
Used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
Therapy	NNP	therapy	therapy	therapi	N	O
to	TO	to	to	to	N	O
Glyburide	NNP	glyburide	glyburide	glyburid	N	O
,	,	,	,	,	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
,	,	,	,	,	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
,	,	,	,	,	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
or	CC	or	or	or	N	O
Compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
Glipizide	VB	glipizide	glipizide	glipizid	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Glyburide	NNP	glyburide	glyburide	glyburid	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Glyburide	NNP	glyburide	glyburide	glyburid	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Glyburide	NNP	glyburide	glyburide	glyburid	N	O

N	NNP	n	n	n	N	O
198	CD	198	198	198	N	O
N	NNP	n	n	n	N	O
99	CD	99	99	99	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
9.6	CD	9.6	9.6	9.6	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
11.1	CD	11.1	11.1	11.1	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
those	DT	those	those	those	N	O
events	NNS	events	event	event	N	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
assistance	NN	assistance	assistance	assist	N	O
or	CC	or	or	or	N	O
exhibiting	VBG	exhibiting	exhibiting	exhibit	N	O
depressed	JJ	depressed	depressed	depress	N	O
level	NN	level	level	level	N	O
or	CC	or	or	or	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
consciousness	NN	consciousness	consciousness	conscious	N	O
or	CC	or	or	or	N	O
seizure	NN	seizure	seizure	seizur	Y	O
.	.	.	.	.	N	O

0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
)(	VBZ	)(	)(	)(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
Metformin	NN	metformin	metformin	metformin	N	O
)	)	)	)	)	N	O

N	NNP	n	n	n	N	O
129	CD	129	129	129	N	O
N	NNP	n	n	n	N	O
129	CD	129	129	129	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
27	CD	27	27	27	N	O
)	)	)	)	)	N	O
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.8	CD	0.8	0.8	0.8	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.6	CD	1.6	1.6	1.6	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Metformin	NNP	metformin	metformin	metformin	N	O

N	NNP	n	n	n	N	O
207	CD	207	207	207	N	O
N	NNP	n	n	n	N	O
104	CD	104	104	104	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2.9	CD	2.9	2.9	2.9	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
-	:	-	-	-	N	O
Metformin	NN	metformin	metformin	metformin	N	O
or	CC	or	or	or	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
)(	VBP	)(	)(	)(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O

N	NNP	n	n	n	N	O
199	CD	199	199	199	N	O
N	NNP	n	n	n	N	O
97	CD	97	97	97	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
7.0	CD	7.0	7.0	7.0	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
Glipizide	NNP	glipizide	glipizide	glipizid	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Glipizide	NNP	glipizide	glipizide	glipizid	N	O

N	NNP	n	n	n	N	O
222	CD	222	222	222	N	O
N	NNP	n	n	n	N	O
219	CD	219	219	219	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
57	CD	57	57	57	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
500	CD	500	500	500	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O

N	NNP	n	n	n	N	O
112	CD	112	112	112	N	O
N	NNP	n	n	n	N	O
109	CD	109	109	109	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

Add	NNP	add	add	add	Y	O
-	:	-	-	-	N	O
On	IN	on	on	on	N	O
to	TO	to	to	to	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Compared	NNP	compared	compared	compar	N	O
to	TO	to	to	to	N	O
Glipizide	NNP	glipizide	glipizide	glipizid	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
Weeks	NNP	weeks	week	week	N	O
)	)	)	)	)	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Glipizide	NNP	glipizide	glipizide	glipizid	N	O
Metformin	NNP	metformin	metformin	metformin	N	O

N	NNP	n	n	n	N	O
877	CD	877	877	877	N	O
N	NNP	n	n	n	N	O
869	CD	869	869	869	N	O

Overall	NNP	overall	overall	overal	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
)	)	)	)	)	N	O
207	CD	207	207	207	N	O
(	(	(	(	(	N	O
23.8	CD	23.8	23.8	23.8	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
0.5	CD	0.5	0.5	0.5	N	O
)	)	)	)	)	N	O

Vital	JJ	vital	vital	vital	N	O
Signs	NNP	signs	sign	sign	N	O

No	DT	no	no	no	N	B-Negation

clinically	RB	clinically	clinically	clinic	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
vital	JJ	vital	vital	vital	N	I-AdverseReaction
signs	NNS	signs	sign	sign	N	I-AdverseReaction
or	CC	or	or	or	N	O
in	IN	in	in	in	N	O
electrocardiograms	NNS	electrocardiograms	electrocardiogram	electrocardiogram	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

No	DT	no	no	no	N	O
clinically	RB	clinically	clinically	clinic	N	O
meaningful	JJ	meaningful	meaningful	meaning	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
hematology	NN	hematology	hematology	hematolog	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
or	CC	or	or	or	N	O
urinalysis	NN	urinalysis	urinalysis	urinalysi	Y	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
enzyme	NN	enzyme	enzyme	enzym	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
fulminant	JJ	fulminant	fulminant	fulmin	N	B-AdverseReaction
hepatic	JJ	hepatic	hepatic	hepat	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
disabling	VBG	disabling	disabling	disabl	N	B-Severity
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Acute	JJ	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
such	JJ	such	such	such	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
potential	JJ	potential	potential	potenti	N	O
causes	NNS	causes	cause	caus	N	O
,	,	,	,	,	N	O
institute	JJ	institute	institute	institut	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
initiate	JJ	initiate	initiate	initi	N	O
alternative	JJ	alternative	alternative	altern	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
:	:	:	:	:	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Causality	NNP	causality	causality	causal	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
detected	VBN	detected	detected	detect	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
and	CC	and	and	and	N	O
assess	JJ	assess	ass	assess	N	O
patient	NN	patient	patient	patient	N	O
for	IN	for	for	for	N	O
probable	JJ	probable	probable	probabl	N	O
cause	NN	cause	cause	caus	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
treat	NN	treat	treat	treat	N	O
cause	NN	cause	cause	caus	N	O
if	IN	if	if	if	N	O
possible	JJ	possible	possible	possibl	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
resolution	NN	resolution	resolution	resolut	N	O
or	CC	or	or	or	N	O
stabilization	NN	stabilization	stabilization	stabil	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
restart	VB	restart	restart	restart	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
if	IN	if	if	if	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
alternative	JJ	alternative	alternative	altern	N	O
etiology	NN	etiology	etiology	etiolog	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
found	VBN	found	found	found	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
When	WRB	when	when	when	N	O
an	DT	an	an	an	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
disabling	VBG	disabling	disabling	disabl	N	B-Severity
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
DPP	NNP	dpp	dpp	dpp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
4	CD	4	4	4	N	I-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
possible	JJ	possible	possible	possibl	N	O
cause	NN	cause	cause	caus	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
joint	NN	joint	joint	joint	N	O
pain	NN	pain	pain	pain	Y	O
and	CC	and	and	and	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
drug	NN	drug	drug	drug	N	O
if	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
outcomes	NNS	outcomes	outcome	outcom	N	O
:	:	:	:	:	N	O
There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
observed	VBN	observed	observed	observ	N	O
carefully	RB	carefully	carefully	care	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
should	MD	should	should	should	N	O
promptly	RB	promptly	promptly	promptli	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
management	NN	management	management	manag	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
whether	IN	whether	whether	whether	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	O
while	IN	while	while	while	N	O
using	VBG	using	using	use	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
include	VBP	include	include	includ	N	O
anaphylaxis	JJ	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	JJ	angioedema	angioedema	angioedema	Y	B-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
for	IN	for	for	for	N	O
other	JJ	other	other	other	N	O
potential	JJ	potential	potential	potenti	N	O
causes	NNS	causes	cause	caus	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
and	CC	and	and	and	N	O
institute	JJ	institute	institute	institut	N	O
alternative	JJ	alternative	alternative	altern	N	O
treatment	NN	treatment	treatment	treatment	N	O
for	IN	for	for	for	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
[	JJ	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
with	IN	with	with	with	N	O
another	DT	another	another	anoth	N	O
DPP	NNP	dpp	dpp	dpp	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
because	IN	because	because	becaus	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
whether	IN	whether	whether	whether	N	O
such	JJ	such	such	such	N	O
patients	NNS	patients	patient	patient	N	O
will	MD	will	will	will	N	O
be	VB	be	be	be	N	O
predisposed	VBN	predisposed	predisposed	predispos	N	O
to	TO	to	to	to	N	O
angioedema	VB	angioedema	angioedema	angioedema	Y	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Effects	NNS	effects	effect	effect	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
nonfatal	JJ	nonfatal	nonfatal	nonfat	N	B-Severity
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
some	DT	some	some	some	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
reports	NNS	reports	report	report	N	O
contain	VBP	contain	contain	contain	N	O
insufficient	JJ	insufficient	insufficient	insuffici	N	O
information	NN	information	information	inform	N	O
necessary	JJ	necessary	necessary	necessari	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
the	DT	the	the	the	N	O
probable	JJ	probable	probable	probabl	N	O
cause	NN	cause	cause	caus	N	O
[	JJ	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
randomized	VBN	randomized	randomized	random	N	O
controlled	JJ	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	B-AdverseReaction
alanine	NN	alanine	alanine	alanin	N	I-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
three	CD	three	three	three	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	I-Severity
ULN	NNP	uln	uln	uln	N	I-Severity
)	)	)	)	)	N	I-Severity
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
:	:	:	:	:	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
in	IN	in	in	in	N	O
alogliptin	JJ	alogliptin	alogliptin	alogliptin	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
comparator	NN	comparator	comparator	compar	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
type	JJ	type	type	type	N	O
2	CD	2	2	2	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
fatty	VBN	fatty	fatty	fatti	N	O
liver	JJ	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
liver	JJ	liver	liver	liver	N	O
test	NN	test	test	test	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
they	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
also	RB	also	also	also	N	O
have	VB	have	have	have	N	O
other	JJ	other	other	other	N	O
forms	NNS	forms	form	form	N	O
of	IN	of	of	of	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
many	JJ	many	many	mani	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
or	CC	or	or	or	N	O
managed	VBN	managed	managed	manag	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
obtaining	VBG	obtaining	obtaining	obtain	N	O
a	DT	a	a	a	N	O
liver	JJ	liver	liver	liver	N	O
test	NN	test	test	test	N	O
panel	NN	panel	panel	panel	N	O
and	CC	and	and	and	N	O
assessing	VBG	assessing	assessing	assess	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
,	,	,	,	,	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
.	.	.	.	.	N	O

Measure	NN	measure	measure	measur	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
promptly	RB	promptly	promptly	promptli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
report	VBP	report	report	report	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
indicate	VB	indicate	indicate	indic	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	O
,	,	,	,	,	N	O
right	JJ	right	right	right	N	O
upper	JJ	upper	upper	upper	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
discomfort	NN	discomfort	discomfort	discomfort	Y	O
,	,	,	,	,	N	O
dark	JJ	dark	dark	dark	N	O
urine	NN	urine	urine	urin	N	O
or	CC	or	or	or	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
clinical	JJ	clinical	clinical	clinic	N	O
context	NN	context	context	context	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
is	VBZ	is	is	is	N	O
found	VBN	found	found	found	N	O
to	TO	to	to	to	N	O
have	VB	have	have	have	N	O
clinically	RB	clinically	clinically	clinic	N	O
significant	JJ	significant	significant	signific	N	O
liver	NN	liver	liver	liver	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
elevations	NNS	elevations	elevation	elev	N	O
and	CC	and	and	and	N	O
if	IN	if	if	if	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
persist	VBP	persist	persist	persist	N	O
or	CC	or	or	or	N	O
worsen	VBP	worsen	worsen	worsen	N	O
,	,	,	,	,	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
and	CC	and	and	and	N	O
investigation	NN	investigation	investigation	investig	Y	O
done	VBN	done	done	done	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
the	DT	the	the	the	N	O
probable	JJ	probable	probable	probabl	N	O
cause	NN	cause	cause	caus	N	O
.	.	.	.	.	N	O

NESINA	NNP	nesina	nesina	nesina	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
restarted	VBN	restarted	restarted	restart	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
another	DT	another	another	anoth	N	O
explanation	NN	explanation	explanation	explan	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
liver	JJ	liver	liver	liver	N	O
test	NN	test	test	test	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Medications	NNP	medications	medication	medic	N	O
Known	NNP	known	known	known	N	O
to	TO	to	to	to	N	O
Cause	VB	cause	cause	caus	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
sulfonylureas	NNS	sulfonylureas	sulfonylurea	sulfonylurea	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Severe	NNP	severe	severe	sever	N	O
and	CC	and	and	and	N	O
Disabling	NNP	disabling	disabling	disabl	N	O
Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
and	CC	and	and	and	N	O
disabling	VBG	disabling	disabling	disabl	N	B-Severity
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
DPP	NNP	dpp	dpp	dpp	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
4	CD	4	4	4	N	I-DrugClass
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	I-DrugClass
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
following	VBG	following	following	follow	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
drug	NN	drug	drug	drug	N	O
therapy	NN	therapy	therapy	therapi	N	O
varied	VBD	varied	varied	vari	N	O
from	IN	from	from	from	N	O
one	CD	one	one	one	N	O
day	NN	day	day	day	N	O
to	TO	to	to	to	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
relief	NN	relief	relief	relief	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
upon	IN	upon	upon	upon	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
medication	NN	medication	medication	medic	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
subset	NN	subset	subset	subset	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
when	WRB	when	when	when	N	O
restarting	VBG	restarting	restarting	restart	N	O
the	DT	the	the	the	N	O
same	JJ	same	same	same	N	O
drug	NN	drug	drug	drug	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
different	JJ	different	different	differ	N	O
DPP	NNP	dpp	dpp	dpp	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
DPP	NNP	dpp	dpp	dpp	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
possible	JJ	possible	possible	possibl	N	O
cause	NN	cause	cause	caus	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
joint	NN	joint	joint	joint	N	O
pain	NN	pain	pain	pain	Y	O
and	CC	and	and	and	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
drug	NN	drug	drug	drug	N	O
if	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
NESINA	NNP	nesina	nesina	nesina	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

